Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

New drug discovery spin-off from CSIRO

CSIRO : 22 July, 2002  (New Product)
CSIRO Entomology today announced the establishment of a company dedicated to producing a wide range of therapeutic drugs from a virtually untapped source, insects.
'Entocosm Pty Ltd has been established to develop the leading global position on developing drugs from insects,' CSIRO's Chief Executive, Dr Geoff Garrett, said.

There are around 250,000 plant species on earth but there are more than four million insect species. Microbial diversity is also huge, although 99% of bacteria cannot be cultured in the laboratory.

'The plant and microbial worlds have long been targets for discovery of therapeutic drugs, but insects have been left virtually untouched,' Dr Garrett said.

'With four million species to be looked at, there is great potential for discovery of hugely important therapeutic drugs in the future.'

Insects utilise an unparalleled array of biologically active substances. These include molecules that kill cancer cells, proteins that prevent blood from clotting, enzymes that degrade pesticides, proteins that glow in the dark, anti-microbial peptides and toxins. Australia, with its mega-diverse biota and advanced scientific infrastructure, offers unique potential for discovery.

Entocosm's Chief Scientific Officer, Dr Stephen Trowell (a CSIRO scientist for the past 13 years), will work with: Emeritus Professor, Rod Rickards, from the Australian National University; and, Clinical Associate Professor at The Canberra Hospital, Peter Collignon, to identify novel drug candidates from insects.

Due to the urgent demand for new agents to treat drug-resistant pathogens, the team will initially focus on discovering new antibiotics.

'Dr Trowell's team has already uncovered a wealth of novel antibiotic potential from insects and the formation of Entocosm Pty Ltd enables the company to screen CSIRO's unique library of insect extracts and develop the novel drug leads through the drug discovery pipeline,' Dr Garrett said.

'CSIRO Entomology has provided many solutions for crop protection, animal health and environmental management and it is exciting to see this new development in the human health area,' he said.

The company has appointed the New York-based firm, Malcolm Binks Associates LLC, as its investment bankers to raise capital from US and Australian investors.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo